GIM
BBIO icon

Glenmede Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Glenmede Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$521K Sell
10,023
-2,986
-23% -$146K ﹤0.01% 917
2025
Q2 		$562K Buy
+13,009
New +$473K ﹤0.01% 884

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Investment Management's BBIO Position: Q3 2025 in Review

Glenmede Investment Management reduced its BridgeBio Pharma (BBIO) stake by 23% in Q3 2025, selling an estimated $146K and leaving 10,023 shares worth $521K. The position accounts for ﹤0.01% of the portfolio, ranked #917.

Glenmede Investment Management first reported a position in BBIO in Q2 2025 and has held it in 2 quarters since. The position peaked at $562K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Glenmede Investment Management held 10,023 shares of BridgeBio Pharma worth $521K as of Q3 2025.
  • Glenmede Investment Management sold 2,986 BridgeBio Pharma shares in Q3 2025, an estimated $146K.
  • BridgeBio Pharma made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #917 holding.
  • Glenmede Investment Management first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's BridgeBio Pharma position peaked at $562K in Q2 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.